Regulatory Update

New York – October 06, 2026 -- Rain, a stablecoin payments infrastructure provider, has filed an application with the Office of the Comptroller of the Currency (OCC) to establish Rain National Trust Bank (RNTB), a proposed federally supervised trust bank headquartered in New York.

RNTB would consolidate custody, reserve management and stablecoin issuance under OCC oversight

If approved, the uninsured national trust bank will provide fiduciary custody of digital assets and US dollars, reserve management for permitted stablecoin issuers, and issuance and redemption of US dollar-backed stablecoins for institutional clients. The entity will not accept deposits, offer consumer accounts, or make commercial loans. Client assets would be segregated from the bank's own holdings and not treated as liabilities, with stablecoin reserves barred from being pledged, lent or reused.

Edmonton – October 06, 2026 -- Aurora Cannabis Inc. (TSX: ACB; NASDAQ: ACB) confirmed that Curaleaf Holdings, Inc. has yet to file a formal Notice of Variation and Change despite announcing intent to revise its hostile takeover bid to an implied US$5.00 per share, comprising 0.4013 Curaleaf subordinate voting shares plus US$1.00 cash per Aurora share.

Los Angeles – October 06, 2026 -- Major League Volleyball (MLV) has introduced a new salary-cap mechanism, the Marquee Player Exception, allowing every team to designate up to two players outside the league's standard cap structure, subject to a luxury tax.

Each team gains two designation slots for elite talent

Teams may name one Seasoned Marquee Player, an established professional athlete meeting league eligibility rules, and one Rookie Marquee Player, an elite collegiate athlete selected through the MLV Draft who joins the league immediately the season after being drafted.

Palm Beach Gardens, Fla. – October 06, 2026 -- AMPERA has submitted a comprehensive Regulatory Engagement Plan to the U.S. Nuclear Regulatory Commission, with plans to file its combined manufacturing and fuel fabrication facility license application by October 2027.

AMPERA targets October 2027 for combined reactor and fuel facility license filing

The submission marks the pre-application phase of the NRC licensing process for AMPERA's advanced reactor technology. The company is providing regulators with detailed design features, methodologies and analysis intended to accelerate and de-risk the review period ahead of the 2027 filing.

Salt Lake City – October 05, 2026 -- Glacis Technologies Inc. has signed a memorandum of understanding with Utah's Office of Artificial Intelligence Policy (OAIP) that makes cryptographically signed AI "receipts" a mandatory condition for vendors and systems operating in the state's Artificial Intelligence Learning Laboratory.

Utah requires a signed receipt for every covered AI inference or safety control evaluation

Under the agreement, designated vendors must generate and deliver a verifiable receipt for every covered AI inference or associated safety and governance control event. The receipts are produced using Glacis technology and mapped to OVERT, an open standard for verifiable evidence of AI operations. OAIP determines which vendors, systems and events fall under the requirement and enforces it through applicable agreements or written designations.

Chicago – October 05, 2026 -- AIRS Medical has secured U.S. FDA 510(k) clearance for SwiftSight Body Composition, an AI-powered MRI analysis tool that quantifies muscle and fat tissue in under five minutes, with SimonMed Imaging confirmed as the first customer to deploy the system.

Scan time under five minutes targets high-volume imaging centers

SwiftSight Body Composition pairs a sub-five-minute MRI scan with automated AI segmentation to measure visceral and subcutaneous fat, abdominal and thigh muscle quantity and quality, bilateral muscle balance, and liver fat via proton density fat fraction. Results are benchmarked against age- and sex-matched reference populations and compiled into a standardized Body Composition Report combining measurements, percentile rankings and visual summaries.

New York – October 05, 2026 -- MobileFuse has secured validation from SBTi Services for a science-based greenhouse gas emissions reduction target, committing the advertising technology company to maintain zero Scope 1 and Scope 2 emissions through 2030.

SBTi classifies MobileFuse's emissions ambition as aligned with a 1.5°C trajectory

The validated target, the most ambitious designation available under the SBTi framework, also requires MobileFuse to measure and reduce its Scope 3 emissions using 2024 as the base year. The company will report progress against the target annually.

MobileFuse joins nearly 12,000 companies with validated science-based targets globally

The validation builds on four consecutive annual greenhouse gas inventories covering 2021 through 2024, each independently verified by The Climate Registry. A fifth annual inventory is currently underway.

New York – October 05, 2026 -- Talkiatry, the largest psychiatric provider group in the U.S., has received The Joint Commission's Gold Seal of Approval® for Behavioral Health, covering care delivered to more than 170 million lives nationwide.

Accreditation follows four million patient visits and rapid national expansion

The accreditation arrives shortly after Talkiatry surpassed four million patient visits and serves as the preferred in-network psychiatry partner for more than 70 U.S. health systems. To earn the designation, the company underwent a comprehensive review of its operations, patient care delivery, and privacy and security practices, followed by on-site surveyor observations and interviews.

Taipei, Shanghai and San Francisco – October 05, 2026 -- HanchorBio, Inc. (TWSE: 7827) said the U.S. Food and Drug Administration has cleared the investigational new drug application for HCB303, clearing the path for the company's second trispecific immunotherapy to enter human testing.

FDA clearance unlocks Phase 1 trial for advanced solid tumors

The clearance allows HanchorBio to launch a Phase 1 first-in-human, dose-escalation, multi-regional study (HCB303-ONC-101) in patients with advanced, relapsed or refractory solid tumors who have exhausted standard treatment options. The trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, biomarkers and preliminary antitumor activity. The decision follows pre-IND feedback HanchorBio received from the FDA in August 2026.

Helsinki – October 05, 2026 -- UPM-Kymmene Corporation and Sappi have received a Letter of Facts from the European Commission restating serious concerns about their proposed graphic paper Joint Venture, the companies disclosed as inside information on October 5, 2026.

Commission maintains objections despite ongoing talks

UPM and Sappi are analyzing the Letter of Facts and preparing a formal response. UPM said it disagrees with the Commission's preliminary assessment and will continue engaging with the review process, while planning to submit remedy proposals that fall short of divestments, citing the transaction's underlying rationale.